Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION

v3.22.4
SEGMENT INFORMATION
3 Months Ended
Jan. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

11. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three months ended January 31, 2023 and 2022 and as of January 31, 2023 and October 31, 2022 (in thousands):

 

    2023     2022  
   

For the Three Months Ended

January 31,

 
    2023     2022  
Net loss:                
CAR-T Therapeutics   $ (911 )   $ (1,611 )
Cancer Vaccines     (958 )     (1,357 )
Anti-Viral Therapeutics     (482 )     (904 )
Other     (3 )     (7 )
Total   $ (2,354 )   $ (3,879 )
                 
Total operating costs and expenses   $ 2,556     $ 3,880  
Less non-cash share-based compensation     (1,063 )     (2,354 )
Operating costs and expenses excluding non-cash share-based compensation   $ 1,493     $ 1,526  
Operating costs and expenses excluding non-cash
share based compensation expense:
               
CAR-T Therapeutics   $ 598     $ 669  
Cancer Vaccines     588       480  
Anti-Viral Therapeutics     305       372  
Other     2       5  
Total   $ 1,493     $ 1,526  

 

                 
    January 31,
2023
    October 31,
2022
 
Total assets:                
CAR-T Therapeutics   $ 11,318     $ 16,921  
Cancer Vaccines     11,098       9,442  
Anti-Viral Therapeutics     5,750       3,811  
Other     140       238  
Total   $ 28,306     $ 30,412  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.